Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 3/20 | 0.40 |
| ▸ | CDK8 | P49336 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010043 | 0.84 | FGFR1 (0.47) | CCNCCDK8GAAFGFR1FGFR2 | |
| SCHEMBL62859 | 0.82 | DHODH (0.48) | CCNCCDK8BRD4DHODHSLC7A5 | |
| SCHEMBL14288603 | 0.73 | PLK1 (0.59) | CCNCCDK8BRD4GAAALDH1A1 | |
| SCHEMBL23471209 | 0.72 | PLK1 (0.42) | CCNCCDK8BRD4GAAALDH1A1 | |
| SCHEMBL3926722 | 0.71 | PLK1 (0.44) | CCNCCDK8BRD4GAAALDH1A1 | |
| SCHEMBL10174741 | 0.70 | PLK1 (0.56) | CCNCCDK8BRD4GAAALDH1A1 | |
| SCHEMBL3931554 | 0.69 | SLC7A5 (0.40) | GAAALDH1A1MAPTTDP1PLK1 | |
| SCHEMBL4010143 | 0.69 | FOLH1 (0.46) | DHODH | |
| SCHEMBL3929387 | 0.68 | FGFR1 (0.40) | BRD4FGFR1FGFR2ALDH1A1MAPT | |
| SCHEMBL15492141 | 0.67 | HDAC8 (0.52) | GAAALDH1A1PLK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | CCNC 2182/4885CDK8 1921/4885BRD4 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.